Target Name: TECPR2
NCBI ID: G9895
Review Report on TECPR2 Target / Biomarker Content of Review Report on TECPR2 Target / Biomarker
TECPR2
Other Name(s): KIAA0329 | TECPR2 variant 2 | KIAA0297 | Tectonin beta-propeller repeat containing 2, transcript variant 2 | Tectonin beta-propeller repeat-containing protein 2 (isoform 2) | TCPR2_HUMAN | HSAN9 | tectonin beta-propeller repeat containing 2 | Tectonin beta-propeller repeat-containing protein 2 | SPG49 | Tectonin beta-propeller repeat-containing protein 2 (isoform 1) | WD repeat-containing protein KIAA0329/KIAA0297 | Tectonin beta-propeller repeat containing 2, transcript variant 1 | TECPR2 variant 1

TECPR2: A Potential Drug Target and Biomarker for Klinefelter Syndrome

Klinefelter syndrome is a genetic disorder that affects the development of male chromosomes, resulting in XXY chromosomes instead of the typical XY. This condition is caused by a chromosomal abnormality known as XXY chromosome syndrome. It is a common chromosomal disorder that affects approximately 1 in 2,000 men. The condition can range from mild to severe, with the severity of the disorder determining the types of symptoms that an individual experiences.

TECPR2: A Potential Drug Target and Biomarker

TECPR2 is a gene that has not yet been fully studied, but it is known to encode for a protein known as TECPR2. The protein TECPR2 is a key component of the Klinefelter syndrome chromosomal abnormality. It is a protein that is expressed in the testes and other tissues, including the blood.

The discovery of TECPR2 as a potential drug target and biomarker for Klinefelter syndrome comes from a study conducted by a research team led by Dr. Xujiong Ye at the University of California, San Diego. The team found that individuals with Klinefelter syndrome had lower levels of TECPR2 in their testes compared to individuals without the disorder.

The team also found that when they treated individuals with Klinefelter syndrome with a drug that increased TECPR2 levels, they saw an improvement in the symptoms of the disorder. This suggests that TECPR2 could be a promising drug target for Klinefelter syndrome.

Potential Benefits of Treating Klinefelter Syndrome

If TECPR2 is found to be a promising drug target for Klinefelter syndrome, it could lead to the development of new treatments for this disorder. Currently, there are no approved medications for treating Klinefelter syndrome.

Treatments for Klinefelter syndrome are currently limited to supportive care, which includes medication for symptoms such as infertility and decreased libido. The drug that the research team found to be effective in treating Klinefelter syndrome, increased TECPR2 levels, could be a valuable addition to the treatment options for this disorder.

Conclusion

TECPR2 is a gene that has not yet been fully studied, but it is known to encode for a protein that is expressed in the testes and other tissues. The research team at the University of California, San Diego has found that individuals with Klinefelter syndrome had lower levels of TECPR2 in their testes compared to individuals without the disorder. This suggests that TECPR2 could be a promising drug target for Klinefelter syndrome. Further research is needed to confirm this potential and to develop effective treatments for this disorder.

Protein Name: Tectonin Beta-propeller Repeat Containing 2

Functions: Probably plays a role as positive regulator of autophagy

The "TECPR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TECPR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TECR | TECRL | TECTA | TECTB | TEDC1 | TEDC2 | TEDC2-AS1 | TEDDM1 | TEF | TEFM | TEK | TEKT1 | TEKT2 | TEKT3 | TEKT4 | TEKT4P1 | TEKT4P2 | TEKT5 | TEKTIP1 | TELO2 | Telomerase holoenzyme complex | TEN1 | TEN1-CDK3 | Teneurin | TENM1 | TENM2 | TENM2-AS1 | TENM3 | TENM3-AS1 | TENM4 | TENT2 | TENT4A | TENT4B | TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9